Myeloid-derived suppressor cells-the new mechanism of immunosuppression in cancer;Komórki supresyjne pochodzące z linii mieloidalnej-nowy mechanizm upos̈ledzenia odpornos̈ci w chorobach nowotworowych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 18-22

  Łuczyński, Włodzimierz ^a   Krawczuk Rybak, Maryna ^a   Stasiak Barmuta, Anna ^b  

^a Klinika Okulistyki Dzieciecej   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cancer; Immunosuppression; Myeloid derived suppressor cells; T regulatory cells

Indexed keywords

ARGINASE; CD11B ANTIGEN; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; CYTOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD11B; ARGINASE; BONE MARROW CELLS; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MYELOID CELLS; NEOPLASMS; NITRIC OXIDE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 38949153176     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S., Carbone D.P., Gabrilovich D.I.: Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol., 2001; 166: 678-689
2. Billiau A.D., Fevery S., Rutgeerts O., Landuyt W., Waer M.: Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood, 2003; 102: 740-748
3. Brito C., Naviliat M., Tiscornia A.C., Vuillier F., Gualco G., Dighiero G., Radi R., Cayota A.M.: Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J. Immunol., 1999; 162: 3356-3366
4. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P.: Identification of CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood, 2000; 96: 3838-3846
5. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S.: Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol., 2006; 176: 284-290
6. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H.: The terminology issue for myeloid-derived suppressor cells. Cancer Res., 2007; 67: 425
7. Gallina G., Dolcetti L., Serafini P., de Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S., Bronte V.: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest., 2006; 116: 2777-2790
8. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., Zitvogel L.: Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med., 2005; 202: 919-929
9. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T.: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 1998; 58: 3761-3764
10. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H.: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and Tcell anergy in tumor-bearing host. Cancer Res., 2006; 66: 1123-1131
11. Kebelmann-Betzing C., Korner G., Badiali L., Buchwald D., Moricke A., Korte A., Köchling J., Wu S., Kappelmeier D., Oettel K., Henze G., Seeger K.: Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor ALL. Cytokine, 2001; 13: 39-50
12. Leite-de-Moraes M.C., Lisbonne M., Arnould A., Machavoine F., Herbelin A., Dy M., Schneider E.: Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: relevance to peripheral myeloid recruitment. Eur. J. Immunol., 2002; 32: 1897-1904
13. uczyñski W., Stasiak-Barmuta A., Iendo E., Kovalchuk O., Krawczuk-Rybak M., Malinowska I., Mitura-Lesiuk M., Chyczewski L., Matysiak M., Kowalczyk J., Jaworowski R.: Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children? Neoplasma, 2006; 53: 301-304
14. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., Zanovello P., Segal D.M.: Myeloid suppressor lines inhibit T cell response by an NO-dependent mechanism. J. Immunol., 2002; 168: 689-695
15. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S., Gabrilovich D.I.: All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res., 2006; 66: 9299-9307
16. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I.: Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res., 2005; 65: 9525-9535
17. Ochoa A.C., Zea A.H., Hernandez C., Rodriquez P.C.: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res., 2007; 13 (2 Pt. 2): 721s-726s
18. Serafini P., Borrello I., Bronte V.: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol., 2006; 16: 53-65
19. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I.: High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recuitment of myeloid suppressor cells. Cancer Res., 2004; 64: 6337-6343
20. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I.: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med., 2006; 203: 2691-2702
21. Seung L., Rowley D., Dubey P., Schreiber H.: Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA, 1995; 92: 6254-6258
22. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S.: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol., 2007; 179: 977-983
23. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S.: Prostaglandin E2 promotes tumor progression by inducing myeloidderived suppressor cells. Cancer Res., 2007; 67: 4507-4513
24. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M.: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res., 2005; 11: 6713-6721
25. Yang R., Cai Z., Zhang Y., Yutzy W.H.4th, Roby K.F., Roden R.B.: CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res., 2006; 66: 6807-6815
26. Young M.R., Lathers D.M.: Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int. J. Immunopharmacol., 1999; 21: 241-252
27. Zea A.H., Rodriquez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C.: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res., 2005; 65: 3044-3048